To investigate whether PFD could play a therapeutic role by inhibiting TGF‐β‐induced metabolic changes during EMT, we used PFD, TGF‐β1 and a TGF‐β receptor inhibitor (LY2109761) to modulate the protein expression of TGF‐β1 in multiple groups in vitro and in vivo. This evidence concerns the gene TGFB1 and polyostotic fibrous dysplasia.